Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant short-term intensive chemoresection vs standard adjuvant intravesical instillations in NMIBC
2017-001189-98Phase 4Completed
- Sponsor
- Aarhus University
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma (TCC) (2 arms), sponsored by Aarhus University. Primary endpoint: Need for repeat TURB or tumor fulguration within 2 years. Started Jun 2017; status: completed.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2017-001189-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001189-98.